Astragaloside IV exhibits anti-tumor function in gastric cancer via targeting circRNA dihydrolipoamide S-succinyltransferase (circDLST)/miR-489-3p/ eukaryotic translation initiation factor 4A1(EIF4A1) pathway.

MLA

Li, Fagen, et al. “Astragaloside IV Exhibits Anti-Tumor Function in Gastric Cancer via Targeting CircRNA Dihydrolipoamide S-Succinyltransferase (CircDLST)/MiR-489-3p/ Eukaryotic Translation Initiation Factor 4A1(EIF4A1) Pathway.” Bioengineered, vol. 13, no. 4, Apr. 2022, pp. 10111–22. EBSCOhost, https://doi.org/10.1080/21655979.2022.2063664.

APA

Li, F., Cao, K., Wang, M., Liu, Y., & Zhang, Y. (2022). Astragaloside IV exhibits anti-tumor function in gastric cancer via targeting circRNA dihydrolipoamide S-succinyltransferase (circDLST)/miR-489-3p/ eukaryotic translation initiation factor 4A1(EIF4A1) pathway. Bioengineered, 13(4), 10111–10122. https://doi.org/10.1080/21655979.2022.2063664

Chicago

Li, Fagen, Ke Cao, Maoyun Wang, Yi Liu, and Yin Zhang. 2022. “Astragaloside IV Exhibits Anti-Tumor Function in Gastric Cancer via Targeting CircRNA Dihydrolipoamide S-Succinyltransferase (CircDLST)/MiR-489-3p/ Eukaryotic Translation Initiation Factor 4A1(EIF4A1) Pathway.” Bioengineered 13 (4): 10111–22. doi:10.1080/21655979.2022.2063664.